Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs

Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Turbachova, I., Eberl, Matthias ORCID: https://orcid.org/0000-0002-9390-5348, Zeidler, J., Lichtenthalter, H. K., Soldati, D. and Beck, E. 1999. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285 (5433) , pp. 1573-1576. 10.1126/science.285.5433.1573

Full text not available from this repository.

Abstract

A mevalonate-independent pathway of isoprenoid biosynthesis present in Plasmodium falciparum was shown to represent an effective target for chemotherapy of malaria. This pathway includes 1-deoxy-D-xylulose 5-phosphate (DOXP) as a key metabolite. The presence of two genes encoding the enzymes DOXP synthase and DOXP reductoisomerase suggests that isoprenoid biosynthesis in P. falciparum depends on the DOXP pathway. This pathway is probably located in the apicoplast. The recombinant P. falciparum DOXP reductoisomerase was inhibited by fosmidomycin and its derivative, FR-900098. Both drugs suppressed the in vitro growth of multidrug-resistant P. falciparum strains. After therapy with these drugs, mice infected with the rodent malaria parasite P. vinckei were cured.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RZ Other systems of medicine
Publisher:	American Association for the Advancement of Science
ISSN:	0036-8075
Last Modified:	27 Oct 2022 09:01
URI:	https://orca.cardiff.ac.uk/id/eprint/64140

Citation Data

Cited 1022 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item